SNGX
Soligenix Inc

12,709
Loading...
Loading...
News
all
press releases
Soligenix to Present at BIO CEO & Investor Conference
Soligenix to Present at BIO CEO & Investor Conference Soligenix to Present at BIO CEO & Investor Conference PR Newswire PRINCETON, N.J., Feb. 4, 2025 PRINCETON, N.J., Feb. 4, 2025 /PRNewswire...
PR Newswire·7mo ago
News Placeholder
More News
News Placeholder
Soligenix to Present at Upcoming Investor Conferences
Soligenix to Present at Upcoming Investor Conferences Soligenix to Present at Upcoming Investor Conferences PR Newswire PRINCETON, N.J., Jan. 16, 2025 PRINCETON, N.J., Jan. 16, 2025 /PRNewswire...
PR Newswire·8mo ago
News Placeholder
HyBryte Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
HyBryte Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma HyBryte Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage...
PR Newswire·8mo ago
News Placeholder
Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma
Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment...
PR Newswire·9mo ago
News Placeholder
HyBryte Clinical Results Demonstrate Continued Improvement Post-Treatment
HyBryte Clinical Results Demonstrate Continued Improvement Post-Treatment HyBryte Clinical Results Demonstrate Continued Improvement Post-Treatment PR Newswire PRINCETON, N.J., Dec. 2, 2024...
PR Newswire·9mo ago
News Placeholder
Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma PR...
PR Newswire·10mo ago
News Placeholder
Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels
Soligenix starts Phase 2 trial of SGX945 for Beh et's Disease, aiming to enroll 25 patients and report results by mid-2025. Trial includes efficacy assessments. read more...
Benzinga·10mo ago
News Placeholder
Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin
Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin PR Newswire PRINCETON, N.J., Oct...
PR Newswire·11mo ago
News Placeholder
Soligenix Invited to Present at Upcoming Investor Conferences
Soligenix Invited to Present at Upcoming Investor Conferences Soligenix Invited to Present at Upcoming Investor Conferences PR Newswire PRINCETON, N.J., Oct. 16, 2024 PRINCETON, N.J., Oct. 16, 2024...
PR Newswire·11mo ago
News Placeholder
HyBryte Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference
HyBryte Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference HyBryte Expanded Treatment Results to be Presented at the European...
PR Newswire·11mo ago

Latest SNGX News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.